This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, J.-M. Articles by Hait, W. N. Search for Related Content PubMed PubMed Citation Articles by Yang, J.-M. Articles by Hait, W. N.

Characteristics of P388/VMDRC.04, a Simple, Sensitive Model for Studying P-Glycoprotein Antagonists¹

Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854 [J-M. Y., W. N. H.], and Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [S. G., M. M. G.]

Cross-resistance to chemotherapeutic drugs is a significant problem in the treatment of patients with cancer. The discovery that this phenomenon is associated with the overexpression of a membrane glycoprotein, P-glycoprotein, which acts as a drug efflux pump, has provided a new target for drug development. To develop a model for identifying new compounds which can block the function of P-glycoprotein, we infected P388 mouse leukemic cells with a retrovirus containing a cloned human MDR1 complementary DNA. The new cell line, P388/VMDRC.04, incorporated and overexpressed the human gene as evidenced by Southern blots, increased mRNA and protein synthesis, and recognition by the MRK16 monoclonal antibody. P388/VMDRC.04 was cross-resistant to colchicine, vincristine, and doxorubicin, and the degree of resistance correlated with a reduction in cellular drug accumulation. Unlike many cell lines selected for resistance by growth in increasing concentrations of drug for prolonged periods of time, these cells did not show alternative mechanisms of resistance such as increased synthesis of glutathione or alterations in topoisomerase II. In addition, the sensitivity of P388/VMDRC.04 cells was completely restored by cyclosporin A and trans-flupenthixol. P388/VMDRC.04 cells were subcloned and 10 clones were picked for in vivo evaluation. One subclone grew similarly to parental cells in female BALB/c x DBA/2 F₁ mice and showed no responsiveness to therapeutic doses of vincristine or etoposide. The combination of vincristine with cyclosporin A significantly increased the survival of mice inoculated with P388/VMDRC.04 cells. The availability of a cell line that displays the MDR phenotype, overexpresses human P-glycoprotein, but does not contain alterations in at least two well-defined alternative mechanisms of resistance, and that can be grown in simple animal models should facilitate the development of new agents active against this form of chemotherapeutic drug resistance.

¹ This work was supported by Grants CA 43888 and CA 08341 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at The Cancer Institute of New Jersey, CABM Building, 679 Hoes Lane, Piscataway, NJ 08854-5638.

Received 7/ 9/93. Accepted 11/29/93.

This article has been cited by other articles:

				S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467. [Abstract] [Full Text] [PDF]

				J. Nagayama, M. Iino, Y. Tada, H. Kusaba, A. Kiue, K. Ohshima, M. Kuwano, and M. Wada Retrovirus insertion and transcriptional activation of the multidrug-resistance gene in leukemias treated by a chemotherapeutic agent in vivo Blood, February 1, 2001; 97(3): 759 - 766. [Abstract] [Full Text] [PDF]

				G. Klopman, L. M. Shi, and A. Ramu Quantitative Structure-Activity Relationship of Multidrug Resistance Reversal Agents Mol. Pharmacol., August 1, 1997; 52(2): 323 - 334. [Abstract] [Full Text]